P1.16-09 Post-Progression Outcomes After Pembrolizumab in Patients with NSCLC and High PD-L1 Expression: Real-World Data from a European Cohort
Metro, G., Signorelli, D., Rey-Cobo, J., Banini, M., Economopoulou, P., Lo Russo, G., Baxevanos, P., Roila, F., De Toma, A., Banna, G., Christopoulou, A., Jimenez, B., Collazo-Lorduy, A., Linardou, H.Volume:
14
Language:
english
Journal:
Journal of Thoracic Oncology
DOI:
10.1016/j.jtho.2019.08.1235
Date:
October, 2019
File:
PDF, 137 KB
english, 2019